Premium
Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide
Author(s) -
Hopkins Ashley M.,
Vitry Agnes I.,
O'Doherty Catherine E.,
Proudman Susanna M.,
Wiese Michael D.
Publication year - 2017
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12717
Subject(s) - leflunomide , medicine , pharmaceutical benefits scheme , rheumatoid arthritis , hydroxychloroquine , methotrexate , sulfasalazine , population , tofacitinib , medical prescription , teriflunomide , pharmacology , disease , fingolimod , immunology , environmental health , covid-19 , ulcerative colitis , infectious disease (medical specialty) , multiple sclerosis